Regenxbio
Open
$8.96
Prev. Close
$8.97
High
$9.00
Low
$8.95
Market Snapshot
$425.23M
-2.2
-4.60
$83.33M
371
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
emptyResult
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Recently from Cashu
Legal Action Against REGENXBIO's Dr. Pakola Highlights Gene Therapy Safety Concerns
Dr. Pakola's Legal Woes Spotlight Safety Concerns in Gene Therapy Dr. Stephen Pakola, M.D., currently serving as the Executive Vice President and Chief Medical Officer at REGENXBIO, faces a securities…
Regenxbio Faces Class Action Lawsuits Over Misleading Claims on RGX-111 Gene Therapy
Legal Challenges Loom for Regenxbio Over RGX-111 Assertions Regenxbio Inc., a biotechnology company specializing in gene therapy, faces significant legal challenges stemming from class action lawsuits…
Regenxbio Sued for Alleged Misleading Claims on Gene Therapy RGX-111 Safety and Efficacy
Regenxbio Faces Legal Scrutiny Over Alleged Misleading Claims About Gene Therapy RGX-111 Regenxbio, Inc., a biotech firm focused on gene therapy innovations, finds itself at the center of a securities…
REGENXBIO Faces Lawsuit Over Misleading Claims on RGX-111 Safety and Investor Trust Issues
### Accountability in Gene Therapy: REGENXBIO's Legal Challenges REGENXBIO, a biotechnology company focused on gene therapy, faces serious legal repercussions following allegations of misleading inves…